PLUS THERAPEUTICS, INC. — Investor Relations & Filings
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's technology platform is designed to deliver high-dose, localized radiation directly to tumors. Its core approach involves encapsulating Rhenium radioisotopes (186Re and 188Re) within nanoliposomes. The lead investigational drug, REYOBIQ™ (rhenium Re186 obisbemeda), is a nanoliposome therapy targeting brain and central nervous system (CNS) cancers, including recurrent glioblastoma and leptomeningeal metastases. A second pipeline program, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is a radioembolization therapy being developed for solid organ cancers, such as liver cancer. The use of Rhenium allows for both therapeutic beta radiation and gamma imaging during treatment.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-15 | English | |
| 10-Q | 2026-05-15 | English | |
| 8-K | 2026-05-15 | English | |
| 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-21 | English | |
| 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-09 | English | |
| 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-08 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46362670 | 8-K | 2026-05-15 | English | ||
| 46362842 | 10-Q | 2026-05-15 | English | ||
| 46361729 | 8-K | 2026-05-15 | English | ||
| 34766221 | 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-21 | English | ||
| 33908386 | 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-09 | English | ||
| 33809270 | 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-04-08 | English | ||
| 33048683 | 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-03-26 | English | ||
| 32887424 | 4 - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-02-27 | English | ||
| 32887423 | 4 - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-02-27 | English | ||
| 32887425 | 8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer) | 2026-02-13 | English | ||
| 27332956 | 8-K Filing | 2026-01-22 | English | ||
| 27332824 | SCHEDULE 13G Filing | 2026-01-22 | English | ||
| 27332868 | 8-K Filing | 2026-01-16 | English | ||
| 27332753 | 424B4 Filing | 2026-01-14 | English | ||
| 27332924 | S-1 Filing | 2026-01-09 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
PLUS THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34301/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34301 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34301 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34301 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34301}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PLUS THERAPEUTICS, INC. (id: 34301)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.